Publications

• Propylene Glycol-Free Melphalan versus PG-Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation for Myeloma.

  (Monahan K, Kleman A, Thapa B, Szabo A, D'Souza A, Dhakal B, Jerkins JH, Pasquini MC, Hamadani M, Hari PN, Chhabra S.) Biol Blood Marrow Transplant. 2020 Dec;26(12):2229-2236 PMID: 32920204 SCOPUS ID: 2-s2.0-85092250990 09/14/2020

• The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study.

  (Cowan AJ, Baldomero H, Atsuta Y, Mikhael J, Aljurf M, Seber A, Greinix H, Koh M, Worel N, Libby EN, Pasquini M, Galeano S, Saber W, Iida M, Jaimovich G, Rolon JM, Kodera Y, Benakli M, Nosa BG, Elhaddad A, Szer J, Passweg J, Kroeger N, Weisdorf D, Niederwieser D.) Biol Blood Marrow Transplant. 2020 Dec;26(12):2372-2377 PMID: 32846200 SCOPUS ID: 2-s2.0-85091208556 08/28/2020

• Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee.

  (Algwaiz G, Aljurf M, Koh M, Horowitz MM, Ljungman P, Weisdorf D, Saber W, Kodera Y, Szer J, Jawdat D, Wood WA, Brazauskas R, Lehmann L, Pasquini MC, Seber A, Lu PH, Atsuta Y, Riches M, Perales MA, Worel N, Okamoto S, Srivastava A, Chemaly RF, Cordonnier C, Dandoy CE, Wingard JR, Kharfan-Dabaja MA, Hamadani M, Majhail NS, Waghmare AA, Chao N, Kröger N, Shaw B, Mohty M, Niederwieser D, Greinix H, Hashmi SK, WBMT and the CIBMTR Health Services and International Studies Committee.) Biol Blood Marrow Transplant. 2020 Dec;26(12):2181-2189 PMID: 32717432 PMCID: PMC7380217 SCOPUS ID: 2-s2.0-85089451061 07/28/2020

• Utilization and Cost Implications of Hematopoietic Progenitor Cells Stored for a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients.

  (Chhabra S, Thapa B, Szabo A, Konings S, D'Souza A, Dhakal B, Jerkins JH, Pasquini MC, Johnson BD, Hari PN, Hamadani M.) Biol Blood Marrow Transplant. 2020 Nov;26(11):2011-2017 PMID: 32717431 SCOPUS ID: 2-s2.0-85090300711 07/28/2020

• Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation.

  (Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Douglas Rizzo J, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M.) Biol Blood Marrow Transplant. 2020 Oct;26(10):1876-1885 PMID: 32653622 PMCID: PMC7571859 SCOPUS ID: 2-s2.0-85089134303 07/13/2020

• Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

  (Holstein SA, Howard A, Avigan D, Bhutani M, Cohen AD, Costa LJ, Dhodapkar MV, Gay F, Gormley N, Green DJ, Hillengass J, Korde N, Li Z, Mailankody S, Neri P, Parekh S, Pasquini MC, Puig N, Roodman GD, Samur MK, Shah N, Shah UA, Shi Q, Spencer A, Suman VJ, Usmani SZ, McCarthy PL.) Biol Blood Marrow Transplant. 2020 Oct;26(10):e247-e255 PMID: 32589921 PMCID: PMC7529908 SCOPUS ID: 2-s2.0-85087955631 06/27/2020

• Clinical characteristics and outcome of SARS-CoV-2-infected patients with haematological diseases: a retrospective case study in four hospitals in Italy, Spain and the Netherlands.

  (van Doesum J, Chinea A, Pagliaro M, Pasquini MC, van Meerten T, Bakker M, Ammatuna E.) Leukemia. 2020 09;34(9):2536-2538 PMID: 32641731 PMCID: PMC7341026 07/10/2020

• Severity of Cytokine Release Syndrome and Its Association with Infections after T Cell-Replete Haploidentical Related Donor Transplantation.

  (Abid MB, Hamadani M, Szabo A, Hari PN, Graham MB, Frank MO, Collier WS, Abedin S, Jerkins JH, Pasquini MC, Runaas L, Shah NN, Chhabra S.) Biol Blood Marrow Transplant. 2020 Sep;26(9):1670-1678 PMID: 32562858 SCOPUS ID: 2-s2.0-85087739042 06/21/2020

• International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.

  (Costa LJ, Derman BA, Bal S, Sidana S, Chhabra S, Silbermann R, Ye JC, Cook G, Cornell RF, Holstein SA, Shi Q, Omel J, Callander NS, Chng WJ, Hungria V, Maiolino A, Stadtmauer E, Giralt S, Pasquini M, Jakubowiak AJ, Morgan GJ, Krishnan A, Jackson GH, Mohty M, Mateos MV, Dimopoulos MA, Facon T, Spencer A, Miguel JS, Hari P, Usmani SZ, Manier S, McCarthy P, Kumar S, Gay F, Paiva B.) Leukemia. 2020 Aug 11 PMID: 32778736 SCOPUS ID: 2-s2.0-85089253567 08/12/2020

• Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes.

  (Olin RL, Fretham C, Pasquini MC, Arora M, Bhatt VR, Derman B, Giralt SA, Huang LW, Koll T, Lee SM, Lin RJ, Pang L, Popat UR, Weisdorf DJ, Artz A.) Blood Adv. 2020 Jun 23;4(12):2810-2820 PMID: 32574365 PMCID: PMC7322958 SCOPUS ID: 2-s2.0-85087009803 06/24/2020

• Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer.

  (Annapragada A, Sikora A, Bollard C, Conejo-Garcia J, Cruz CR, Demehri S, Demetriou M, Demirdjian L, Fong L, Horowitz M, Hutson A, Kadash-Edmondson K, Kufe D, Lipkin S, Liu S, McCarthy C, Morgan M, Morris Z, Pan Y, Pasquini M, Schoenberger S, Van Allen E, Vilar E, Xing Y, Zha W, IOTN Consortium, Odunsi A.) J Immunother Cancer. 2020 06;8(1) PMID: 32554617 PMCID: PMC7304845 SCOPUS ID: 2-s2.0-85086691799 06/20/2020

• Adjuvant doxycycline to enhance anti-amyloid effects: Results from the dual phase 2 trial.

  (D'Souza A, Szabo A, Flynn KE, Dhakal B, Chhabra S, Pasquini MC, Weihrauch D, Hari PN.) EClinicalMedicine. 2020 Jun;23:100361 PMID: 32529175 PMCID: PMC7280748 06/13/2020